LLY Olomorasib: Second BTD Targets Pancreatic Cancer

Eli Lilly (LLY) closed Friday at $1,148.84 with a $1.02 trillion market cap. Today the FDA granted Breakthrough Therapy designation to olomorasib (LY3537982) as monotherapy for previously treated KRAS G12C-mutant advanced pancreatic cancer. This is the second BTD for the drug; the first came in September 2025 for first-line NSCLC in combination with pembrolizumab. Neither designation will move Lilly’s stock. But the pancreatic cancer BTD tells you something important about where the KRAS G12C inhibitor market is heading.

Why Pancreatic Cancer Matters More Than NSCLC

The NSCLC BTD was expected. Amgen’s Lumakras (sotorasib) and BMS’s Krazati (adagrasib) are already approved in second-line KRAS G12C NSCLC. The field is crowded. Olomorasib’s NSCLC BTD positions it as a next-generation competitor in a market that already has two approved drugs. The pancreatic cancer BTD is different. No approved therapy specifically targets KRAS G12C-mutant pancreatic cancer. Lilly could be first in that indication.

Here is why that matters. Pancreatic cancer is diagnosed in approximately 60,000 people in the US each year, with 50,000 deaths. The five-year survival rate is under 5%. KRAS mutations are found in roughly 90% of pancreatic cancers, and the G12C subtype accounts for approximately 1% to 2% of those cases. That means roughly 600 to 1,200 US patients per year carry the G12C mutation in pancreatic cancer. It is a small population, but it is a population with zero targeted options and a median survival under 12 months.

The FDA granted the BTD based on preliminary data from the Phase 1/2 LOXO-RAS-20001 trial (NCT04956640). Across 195 patients with KRAS G12C-mutant solid tumors, olomorasib monotherapy showed a 37.4% ORR (95% CI: 29.4 to 46.0) in 139 non-CRC patients, with a disease control rate of 89.5%. The Nature Communications publication confirmed predominantly grade 1 to 2 treatment-related adverse events with no grade 4 or 5 TRAEs. The specific pancreatic cancer subset data that earned the BTD has not been fully disclosed, but the overall monotherapy activity is consistent across tumor types.

Competitive Context: First-Gen KRAS G12C Inhibitors in Pancreatic Cancer

Amgen tested sotorasib in KRAS G12C-mutant pancreatic cancer in the CodeBreaK 100 trial. Published in NEJM, the trial enrolled 38 patients and showed a 21.1% ORR (8 confirmed responses) with a disease control rate of 84.2%. The median PFS was 4 months and median duration of response was 6 months. Sotorasib is not approved for pancreatic cancer; it is approved for NSCLC and, in combination with panitumumab, for colorectal cancer. Adagrasib (Krazati) has shown similar activity in pancreatic cancer in a Phase 1/2 trial but also lacks a pancreatic cancer approval.

Olomorasib’s 37.4% ORR across non-CRC solid tumors compares favorably to sotorasib’s 21.1% in pancreatic cancer specifically. But cross-trial comparisons are unreliable. The LOXO-RAS-20001 trial included multiple tumor types, and the pancreatic cancer-specific response rate has not been disclosed. What the BTD tells us is that the FDA saw enough in the pancreatic subset to grant expedited review. The specific pancreatic ORR will be the number to watch at the next data disclosure.

The safety profile is the other differentiator. First-generation KRAS G12C inhibitors have been hampered by dose-limiting toxicities, particularly hepatotoxicity and gastrointestinal effects, which complicate combination strategies with checkpoint inhibitors. Olomorasib’s Phase 1 data showed predominantly grade 1 to 2 treatment-related adverse events with infrequent grade 3 events and no grade 4 or 5 TRAEs. The cleaner safety profile is what enables the combination with pembrolizumab in first-line NSCLC. In pancreatic cancer, where patients are often heavily pretreated and have compromised organ function, a better-tolerated KRAS G12C inhibitor could meaningfully expand the treatable population.

Olomorasib was designed as a next-generation KRAS G12C inhibitor with higher target occupancy than first-generation agents. In preclinical models, it demonstrated more potent tumor growth inhibition than sotorasib or adagrasib. The clinical data so far supports the “next-gen” claim: 37.4% monotherapy ORR with a clean safety profile is competitive. But the drug is still in Phase 1/2 for pancreatic cancer. The registrational trials, SUNRAY-01 and SUNRAY-02, are in NSCLC, not pancreatic cancer. A pancreatic cancer registrational trial has not been initiated.

Valuation: Immaterial at $1 Trillion

Lilly’s Q4 2025 revenue was $19.29 billion. Annualized, the company generates approximately $77 billion in revenue. Olomorasib’s peak sales in pancreatic cancer, even at first-in-indication pricing, would be modest. At 600 to 1,200 US patients per year and a typical oncology drug cost of $15,000 to $20,000 per month, the pancreatic cancer opportunity is roughly $100 to $300 million annually. That is 0.1% to 0.4% of Lilly’s revenue base.

This is the pan-KRAS large-cap immateriality framing from the BBOT analysis in action. The pancreatic cancer BTD is a pipeline signal, not a stock catalyst. Lilly’s stock will not move on this news because the revenue contribution is a rounding error. What matters is the broader olomorasib franchise: the NSCLC Phase 3 trials (SUNRAY-01, SUNRAY-02) target a much larger market. KRAS G12C-mutant NSCLC represents approximately 14% of NSCLC cases, and NSCLC is the largest oncology market by patient count. If olomorasib wins in first-line NSCLC, the drug could generate $2 to $4 billion at peak.

But Lilly’s GLP-1 and obesity franchise (retatrutide Phase 3) (Mounjaro, Zepbound) is the stock’s actual driver. The obesity and diabetes market is projected to exceed $100 billion annually by 2030, and Lilly and Novo Nordisk are the two companies capturing the majority of that revenue. The ongoing GLP-1 advertising lawsuit between Novo and Lilly shows how high the stakes are. The oncology pipeline, including olomorasib, is incremental option value on top of a metabolic disease juggernaut. At $1.02 trillion market cap, Lilly trades at approximately 13x revenue. Investors are paying for the obesity and diabetes franchise, not a KRAS G12C inhibitor that is still in Phase 1/2 for its newest indication.

Risks

The pancreatic cancer BTD is based on Phase 1/2 data, and the specific pancreatic subset ORR has not been disclosed. If the pancreatic-specific response rate is closer to sotorasib’s 21% than the 37% pan-tumor average, the BTD may not translate into an approval. The FDA grants BTD based on preliminary evidence; it does not guarantee approval.

A pancreatic cancer registrational trial has not been initiated, which is the deeper problem. The SUNRAY trials are in NSCLC. A pancreatic cancer trial would need to enroll 600 to 1,200 patients from a population of 600 to 1,200 annual cases in the US. Enrollment will be slow and the trial will take years. This is not a near-term catalyst. The competitive field is not standing still either. Amgen and BMS are both pursuing label expansions for their first-generation KRAS G12C inhibitors. If either sotorasib or adagrasib wins a pancreatic cancer approval before olomorasib, the first-in-indication advantage disappears. Lilly’s next-generation profile (higher potency, cleaner safety) may still differentiate, but being second to market in pancreatic cancer would reduce the commercial opportunity.

Verdict

The pancreatic cancer BTD is good news for Lilly’s oncology pipeline. It is not good news for the stock. At $1.02 trillion market cap, olomorasib’s pancreatic cancer opportunity is immaterial to the investment thesis. Hold LLY for the GLP-1 franchise. Watch olomorasib’s NSCLC Phase 3 readout (SUNRAY-01) as the pipeline catalyst that could add option value. The pancreatic cancer BTD is a pipeline signal, not a trade trigger.

For investors who want pure-play KRAS exposure, Lilly is the wrong vehicle. The KRAS G12C inhibitor market is where ADCs were five years ago: crowded in the lead indication, with differentiation shifting to next-generation chemistry and pan-tumor expansion. The company that wins first-in-indication in pancreatic cancer gets a small but meaningful franchise. Lilly has the BTD. Now it needs the trial.